320 related articles for article (PubMed ID: 32630614)
1. Therapeutic Editing of the
Mirgayazova R; Khadiullina R; Chasov V; Mingaleeva R; Miftakhova R; Rizvanov A; Bulatov E
Genes (Basel); 2020 Jun; 11(6):. PubMed ID: 32630614
[TBL] [Abstract][Full Text] [Related]
2. Parallel CRISPR-Cas9 screens clarify impacts of p53 on screen performance.
Bowden AR; Morales-Juarez DA; Sczaniecka-Clift M; Agudo MM; Lukashchuk N; Thomas JC; Jackson SP
Elife; 2020 May; 9():. PubMed ID: 32441252
[TBL] [Abstract][Full Text] [Related]
3. CRISPR/Cas9 treatment causes extended TP53-dependent cell cycle arrest in human cells.
Geisinger JM; Stearns T
Nucleic Acids Res; 2020 Sep; 48(16):9067-9081. PubMed ID: 32687165
[TBL] [Abstract][Full Text] [Related]
4. Restoring the p53 'Guardian' Phenotype in p53-Deficient Tumor Cells with CRISPR/Cas9.
Chira S; Gulei D; Hajitou A; Berindan-Neagoe I
Trends Biotechnol; 2018 Jul; 36(7):653-660. PubMed ID: 29478674
[TBL] [Abstract][Full Text] [Related]
5. Application of prime editing system to introduce TP53 R248Q hotspot mutation in acute lymphoblastic leukemia cell line.
Nguyen T; Aida T; Iijima-Yamashita Y; Tamai M; Nagamachi A; Kagami K; Komatsu C; Kasai S; Akahane K; Goi K; Inaba T; Sanada M; Inukai T
Cancer Sci; 2024 Jun; 115(6):1924-1935. PubMed ID: 38549229
[TBL] [Abstract][Full Text] [Related]
6. Generation of a TP53-modified porcine cancer model by CRISPR/Cas9-mediated gene modification in porcine zygotes via electroporation.
Tanihara F; Hirata M; Nguyen NT; Le QA; Hirano T; Takemoto T; Nakai M; Fuchimoto DI; Otoi T
PLoS One; 2018; 13(10):e0206360. PubMed ID: 30352075
[TBL] [Abstract][Full Text] [Related]
7. CRISPR/Cas9 gene-editing strategies in cardiovascular cells.
Vermersch E; Jouve C; Hulot JS
Cardiovasc Res; 2020 Apr; 116(5):894-907. PubMed ID: 31584620
[TBL] [Abstract][Full Text] [Related]
8. [Precision gene editing technologies based on CRISPR/Cas9: a review].
Xue S; Wang S; Liu L; Zhong Q; Cheng Z; Xiao S
Sheng Wu Gong Cheng Xue Bao; 2023 Jul; 39(7):2566-2578. PubMed ID: 37584115
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of the CRISPR/Cas9 directed mutant TP53 gene repairing effect in human prostate cancer cell line PC-3.
Batır MB; Şahin E; Çam FS
Mol Biol Rep; 2019 Dec; 46(6):6471-6484. PubMed ID: 31571107
[TBL] [Abstract][Full Text] [Related]
10. CRISPR-Cas9, A Promising Therapeutic Tool for Cancer Therapy: A Review.
Akram F; Ikram Ul Haq ; Ahmed Z; Khan H; Ali MS
Protein Pept Lett; 2020; 27(10):931-944. PubMed ID: 32264803
[TBL] [Abstract][Full Text] [Related]
11. Reverting
Abuhamad AY; Mohamad Zamberi NN; Sheen L; Naes SM; Mohd Yusuf SNH; Ahmad Tajudin A; Mohtar MA; Amir Hamzah AS; Syafruddin SE
Cells; 2022 May; 11(10):. PubMed ID: 35626649
[TBL] [Abstract][Full Text] [Related]
12. CRISPR/Cas9 application in cancer therapy: a pioneering genome editing tool.
Shojaei Baghini S; Gardanova ZR; Abadi SAH; Zaman BA; İlhan A; Shomali N; Adili A; Moghaddar R; Yaseri AF
Cell Mol Biol Lett; 2022 May; 27(1):35. PubMed ID: 35508982
[TBL] [Abstract][Full Text] [Related]
13. CRISPR/Cas mediated epigenome editing for cancer therapy.
Ansari I; Chaturvedi A; Chitkara D; Singh S
Semin Cancer Biol; 2022 Aug; 83():570-583. PubMed ID: 33421620
[TBL] [Abstract][Full Text] [Related]
14. CRISPR/Cas9 ribonucleoprotein-mediated genome and epigenome editing in mammalian cells.
Bloomer H; Khirallah J; Li Y; Xu Q
Adv Drug Deliv Rev; 2022 Feb; 181():114087. PubMed ID: 34942274
[TBL] [Abstract][Full Text] [Related]
15. CRISPR/Cas9 technology as a potent molecular tool for gene therapy.
Karimian A; Azizian K; Parsian H; Rafieian S; Shafiei-Irannejad V; Kheyrollah M; Yousefi M; Majidinia M; Yousefi B
J Cell Physiol; 2019 Aug; 234(8):12267-12277. PubMed ID: 30697727
[TBL] [Abstract][Full Text] [Related]
16. Application of CRISPR/Cas9 gene editing technique in the study of cancer treatment.
Jiang C; Meng L; Yang B; Luo X
Clin Genet; 2020 Jan; 97(1):73-88. PubMed ID: 31231788
[TBL] [Abstract][Full Text] [Related]
17. CRISPR/Cas9-based epigenome editing: An overview of dCas9-based tools with special emphasis on off-target activity.
Tadić V; Josipović G; Zoldoš V; Vojta A
Methods; 2019 Jul; 164-165():109-119. PubMed ID: 31071448
[TBL] [Abstract][Full Text] [Related]
18. CRISPR-Cas9 genome editing induces a p53-mediated DNA damage response.
Haapaniemi E; Botla S; Persson J; Schmierer B; Taipale J
Nat Med; 2018 Jul; 24(7):927-930. PubMed ID: 29892067
[TBL] [Abstract][Full Text] [Related]
19. Therapeutic Genome Editing and In Vivo Delivery.
Ramirez-Phillips AC; Liu D
AAPS J; 2021 Jun; 23(4):80. PubMed ID: 34080099
[TBL] [Abstract][Full Text] [Related]
20. CRISPR/Cas9 gene editing: a new approach for overcoming drug resistance in cancer.
Vaghari-Tabari M; Hassanpour P; Sadeghsoltani F; Malakoti F; Alemi F; Qujeq D; Asemi Z; Yousefi B
Cell Mol Biol Lett; 2022 Jun; 27(1):49. PubMed ID: 35715750
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]